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Abstract
Introduction Women younger than 35 years who are diagnosed
with breast cancer tend to have more advanced stage tumors
and poorer prognoses than do older women. Pregnancy is
associated with elevated exposure to estrogen, which may
influence the progression of breast cancer in young women. The
objective of the present study was to examine the relationship
between reproductive events and tumor stage, grade, estrogen
receptor and progesterone receptor status, and survival in
women diagnosed with early-onset breast cancer.
Methods In a population-based, case–case study of 254
women diagnosed with invasive breast cancer at age under 35
years, odds ratios (ORs) and 95% confidence intervals (CIs)
were estimated using unconditional logistic regression with
tumor characteristics as dependent variables and adjusting for
age and education. Survival analyses also examined the
relationship between reproductive events and overall survival.
Results Compared with nulliparous women, women with three
or more childbirths were more likely to be diagnosed with
nonlocalized tumors (OR = 3.1, 95% CI = 1.3–7.7), and early
age (<20 years) at first full-term pregnancy was also associated
with a diagnosis of breast cancer that was nonlocalized (OR =
3.0, 95% CI = 1.2–7.4) and of higher grade (OR = 3.2, 95% CI
1.0–9.9). The hazard ratio for death among women with two or
more full-term pregnancies, as compared with those with one
full-term pregnancy or none, was 2.1 (95% CI = 1.0–4.5),
adjusting for stage. Among parous women, those who lactated
were at decreased risk for both estrogen receptor and
progesterone receptor negative tumors (OR = 0.2, 95% CI =
0.1–0.5, and OR = 0.4, 95% CI = 0.2–0.8, respectively).
Conclusion The results of the present study suggest that
pregnancy and lactation may influence tumor presentation and
survival in women with early-onset breast cancer.
Introduction
Invasive breast cancer among women younger than 35 years
is relatively rare in comparison with breast cancer in older
women; only 2% of diagnoses occur in the younger age group
[1]. However, it is the leading type of cancer and cause of can-
cer-related death in women aged 15–34 years [2]. Prognosis
following diagnosis for younger women is worse; they have
shorter recurrence-free and overall survival than do older pre-
menopausal [3] and post-menopausal [4] women.
Malignant breast tumors in women younger than 35 years tend
to have features that are characteristic of more aggressive or
advanced tumors compared with tumors in older women. The
tumors in younger women tend to be larger, have more nodal
involvement, are more poorly differentiated, and are more often
estrogen receptor (ER) negative than are tumors in older
women [3,5]. These tumor variables have been associated
with poorer overall survival. Although there is evidence linking
tumor factors with recurrence-free and overall survival, little is
known about host characteristics that may contribute to differ-
ences in tumor variables observed at diagnosis, particularly in
young women, who as a group are not subject to the same
screening practices (namely mammography) as their older
counterparts. An understanding of host variables that influ-
ence stage at presentation and other tumor characteristics
may help to elucidate the mechanisms that are involved in
tumor progression in early-onset breast cancer.
Pregnancy and childbirth are generally believed to reduce a
woman's long-term risk for breast cancer. However, some
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studies have documented a transient increase in risk in the
years immediately following childbirth [6-8], and a decrease in
survival for women diagnosed in the years following childbirth
[9,10].
Early detection is a key factor in determining whether a woman
will survive a breast cancer diagnosis. Advances in screening
methods have lead to a significant decrease in the percentage
of diagnoses of late-stage disease in the past decade [11].
However, women younger than 40 years are generally not
included in recommendations regarding who should undergo
screening mammograms in the USA.
The observation that women with breast cancer under age 35
years are more likely to be diagnosed with advanced stage dis-
ease [3,5] and to have poorer survival than older women, com-
bined with the fact that these women are not included in
mammogram screening recommendations, underscores the
importance of uncovering the processes of disease progres-
sion in these women so that effective, targeted strategies for
early detection and management of this disease may be devel-
oped. The present study examines the relationships between
reproductive and hormonal factors, stage, grade, hormone
receptor status, and survival among women diagnosed with
breast cancer at age under 35 years.
Materials and methods
Study design
A population-based, case–case design was used to examine
the relationships between host reproductive and other varia-
bles, and tumor characteristics at presentation in breast can-
cer patients diagnosed at an early age.
Population under study
The study included 298 patients with early-onset (diagnosed
at age <35 years) breast cancer. Eligible participants were all
women aged between 18 and 34 years residing in one of 38
of the 58 California counties (n = 169), in Connecticut (n =
60), or in Massachusetts (n = 69) at the time of diagnosis. The
participation rate was 65% for patients from California, 61%
for patients from Connecticut, and 55% for patients from
Massachusetts.
The women were diagnosed with invasive breast cancer
between 1 January 1995 and 31 December 1996. The
patients had to be living at the time of contact. Women who
met these criteria were identified through the state or regional
cancer registries of California, Connecticut, and Massachu-
setts. Twenty-eight women in California, one woman in Massa-
chusetts, and no women in Connecticut died before study
contact. Limited data on nonparticipants from California
allowed for a comparison of demographic variables between
participants and nonparticipants. Although there were no sig-
nificant age differences between participants (mean 31.3
years) and nonparticipants (mean 30.9 years), participants
(73%) were more likely to be non-Hispanic white than were
nonparticipants (59%).
Protocol
Before contact with any potential participants, approval was
obtained from the local institutional review boards at partici-
pating centers. Consent to participate was first obtained from
the treating physician. Potential participants were then mailed
introductory letters and response forms. Trained interviewers
telephoned participants to conduct a structured telephone
interview and to schedule an appointment to collect a blood
sample. Participants completed a written informed consent
and a release of medical information form. The mean time
between diagnosis and interview was 11.5 months (range 0–
27 months).
Data collection and measurement tools
The interviews obtained information on host characteristics
including age, demographic information, reproductive varia-
bles (age at menarche, pregnancy and childbirth history, his-
tory of spontaneous or induced abortions, lactation history),
self-reported family history of cancer, and oral contraceptive
and other hormone medication use.
Data on tumor characteristics were available for 254 (85.2%)
participants from the cancer registry databases and pathology
reports, and these women comprised the study group. Infor-
mation on tumor characteristics was collected at the time of
diagnosis, including tumor site, histology, laterality, behavior,
grade, stage, tumor size, and ER and progesterone receptor
(PgR) status.
Cancer registry and SEER linkage
The California Cancer Registry abstracts for all of the Califor-
nia patients were available and were the primary source of
tumor characteristic and follow-up data for these patients.
The 60 Connecticut patients were linked with the National
Cancer Institute's Surveillance, Epidemiology, and End
Results (SEER) Program's 1973–1999 public use data files
[12] to obtain tumor characteristics and vital status updates.
Because personal identifiers were used only by the centers
that conducted the telephone interviews and were not availa-
ble in the analysis data set for these patients, linkage was per-
formed using the following variables, if these tumor
characteristics were also available from pathology reports:
year of birth, age at diagnosis, month and year of diagnosis,
marital status, race, and tumor characteristics (site, histology,
laterality, behavior, grade, stage, ER/PgR status, and size).
There were 60 patients who participated in the Early Onset
Breast Cancer Study and who were Connecticut residents at
the time of diagnosis. All of the 60 participants were linked to
the SEER records using the variables listed above.Available online http://breast-cancer-research.com/content/7/4/R541
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Pathology reports
Tumor data for the Massachusetts patients were ascertained
using pathology reports. Pathology reports were available for
25 of the patients from Massachusetts and were reviewed by
a certified tumor registrar and coded for tumor site, histology,
laterality, behavior, grade, size, and SEER summary stage.
Where available, pathology reports were also used to supple-
ment tumor data for the patients from California and
Connecticut.
Stage determination
The SEER summary stage classifies tumors into one of the fol-
lowing categories [13]: in situ, localized, regional by direct
extension, regional by nodes, regional by nodes and direct
extension, distant, or unstaged based on the SEER guidelines.
Another staging system reported for the patients from Califor-
nia was the TNM staging system, which follows the American
Joint Commission on Cancer (AJCC) criteria and consists of
assigning appropriate letters or numbers to the following three
fields [14]: T (primary tumor), N (nodal involvement), and M
(distant metastasis). This classification is recorded for both
clinical and pathological staging.
These sources of tumor staging information resulted in a total
sample of 247 with stage classification as either localized
(invasive carcinoma confined to the breast) or nonlocalized
(invasive carcinoma spread beyond the breast, by direct exten-
sion and/or to regional lymph nodes, and/or by direct exten-
sion beyond adjacent organs specified as regional, metastasis
to distant lymph nodes, or development of discontinuous sec-
ondary or metastatic tumors).
Grade
Tumors were classified according to histologic grade or
degree of differentiation, as coded in the registry databases or
pathology reports. This measures the degree to which the
tumor cells have the differentiated or specialized characteris-
tics of the tissue or organ in which they are found. Tumor
grade information was available for 213 participants.
Estrogen receptor/progesterone receptor status
Tumors classified as borderline for hormone receptor status
were considered positive (n = 3 for ER status; n = 3 for PgR
status). A total of 182 and 176 records contained information
on ER and PgR status, respectively.
Reproductive/hormonal variables
Reproductive variables and hormonal exposures were
assessed using the personal interview data available for all
298 study participants.
Family history status
Family history of cancer was assessed during the personal
interview. A positive family history was considered to be at
least one first-degree female relative (mother or sister) diag-
nosed with breast or ovarian cancer. Adopted participants
were excluded from the family history analyses (n = 2), leaving
296 with complete family history information.
Statistical analysis
Tumor presentation
Analyses were completed to assess whether host characteris-
tics (including reproductive/hormonal and family history varia-
bles) were associated with tumor characteristics indicative of
advanced or aggressive disease (including tumor stage,
grade, and ER/PgR status), adjusting for age at diagnosis and
education (higher of self or spouse). Odds ratios (ORs) were
calculated using unconditional logistic regression with tumor
characteristics as the dependent variables (localized versus
nonlocalized disease; grade 1–2 tumors versus grade 3–4
tumors; ER positive versus ER negative; PgR positive versus
PgR negative). Trend tests for select variables were performed
by regressing categorical variables as continuous. All analyses
were performed using SAS version 8.2 (SAS Institute Inc.,
Cary, NC, USA).
Survival analysis
Data on follow up were obtained for the California cases
through 31 December 2001 from the California Cancer Reg-
istry and for the Connecticut cases through 31 December
1999 from the SEER 1999 public use data file [12]. Follow-up
data were not available for the patients from Massachusetts.
Survival time was truncated at 60 months for the 40 California
cases with follow-up information beyond 60 months. A
woman's survival time was censored if the woman was known
to be alive at the date of last follow up. Kaplan–Meier product
limit curves were generated to examine the associations
between demographic and reproductive characteristics and
overall survival following breast cancer diagnosis. The Wil-
coxon test was used to test the equality of the overall survivor
functions across groups. The effects of reproductive factors
on survival were also quantified with relative risk estimates
(and 95% confidence intervals [CIs]) calculated using Cox
proportional hazards regression analysis, adjusting for breast
cancer stage.
Results
Demographic and tumor characteristics of the 254 women
studied are summarized in Table 1. Seventy-six per cent of
tumors were classified as infiltrating duct carcinoma. Stage
was localized in 51.6%, nonlocalized in 45.7%, and unknown
in 2.8% of cases. The majority of tumors were self-detected
(80.7%). Age at diagnosis ranged from 20 to 34 years, with
75.6% of cases occurring between ages 30 and 34 years. The
majority of patients (72.8%) were non-Hispanic Caucasians.
Reproductive and hormonal factors and tumor 
characteristics
Age- and education-adjusted analyses of reproductive events
occurring before diagnosis and tumor characteristics areBreast Cancer Research    Vol 7 No 4    Largent et al.
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Table 1
Demographic and tumor characteristics of early onset breast cancer patients
Characteristic Frequency (n)%
Age at diagnosis (years)
20–24 7 2.7
25–29 55 21.6
30–34 192 75.6
Race/ethnicity
Non-Hispanic white 185 72.8
African-American 17 6.7
Hispanic 33 13.0
Asian/Pacific islander 5 2.0
Native American 1 0.4
Other 13 5.1
Education
Less than college degree 143 56.3
College graduate 111 43.7
Histology
Infiltrating duct carcinoma 193 76.0
Comedocarcinoma 15 5.9
Medullary carcinoma 9 3.5
Lobular carcinoma 8 3.2
Infiltrating duct and lobular carcinoma 8 3.2
Other 21 8.3
Stage
Localized 131 51.6
Nonlocalized 116 45.7
Unknown 7 2.8
Grade/differentiation
Grade I/well differentiated 9 3.0
Grade II/moderately differentiated 72 24.2
Grade III/poorly differentiated 124 41.6
Grade IV/undifferentiated 8 2.7
Grade not determined/not stated/NA 85 28.5
Laterality
Right 132 52.0
Left 122 48.0
Estrogen receptor status
Positive 92 36.2
Negative 87 34.2
Borderline 3 1.2Available online http://breast-cancer-research.com/content/7/4/R541
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summarized in Tables 2, 3, 4, 5. Reproductive variables
include age at menarche, age at first full-term pregnancy, total
number of live births, total number of miscarriages and
induced abortions, breastfeeding history, months between last
full-term pregnancy and diagnosis, and oral contraceptive use.
Tumor characteristics include stage at diagnosis, grade, ER,
and PgR status.
Analyses of breast cancer stage included 247 women for
whom tumor stage data were available (Table 2). Women with
a first full-term pregnancy at age under 20 years were three
times as likely to be diagnosed with nonlocalized disease than
were women with no full-term pregnancies (OR = 3.0, 95% CI
1.2–7.4). This OR decreased as age at first full-term preg-
nancy increased (P for trend < 0.01). However, when this
analysis was restricted to parous women there were no signif-
icant associations between age at first full-term pregnancy and
stage (for age 20–24 years: OR = 0.7, 95% CI = 0.3–1.7; for
age 25–29 years: OR = 0.5, 95% CI = 0.2–1.4; for age 30–
34 years: OR = 0.3, 95% CI = 0.1–1.1; versus age <20
years). Women who had three or more live births were about
three times more likely to be diagnosed with nonlocalized
disease than were women who did not have any live births.
When this analysis was restricted to only gravid women, those
with three or more pregnancies were more likely to be diag-
nosed with more advanced stage breast cancer than were
women who reported one to two pregnancies (OR = 2.3, 95%
CI = 1.2–4.3). Number of births and age at first full-term preg-
nancy were highly correlated, and when terms for both were
included in a logistic regression model neither was found to
remain statistically significant (data not shown). Age at
menarche, total number of miscarriages, total number of
induced abortions, time since last full-term pregnancy, breast-
feeding history, and oral contraceptive use were not found to
be significantly associated with stage.
Analyses of tumor grade included the 213 women for whom
data on tumor grade were available. Early age at first full-term
pregnancy was the only reproductive variable examined that
was found to be significantly associated with higher tumor
grade. Women who had a first full-term pregnancy at age
under 20 years were significantly more likely to have tumors of
grade 3–4 than were nulliparous women. The other reproduc-
tive and family history variables examined were not found to be
significantly associated with tumor grade (Table 3).
The analyses of ER and PgR status included the 182 and 176
women, respectively, for whom data on ER and PgR status
were available (Tables 4 and 5). Breastfeeding history was the
only reproductive variable found to be significantly associated
with both ER and PgR status. Among parous women, those
who reported ever breastfeeding were significantly more likely
to have ER-positive tumors and PgR-positive tumors. Other
reproductive variables examined were not found to be signifi-
cantly associated with either ER or PgR status.
Family history and tumor characteristics
A family history of breast or ovarian cancer in a mother or sister
was examined in relation to tumor characteristics. Having a
mother or sister with a diagnosis of breast or ovarian cancer
was not significantly associated with tumor stage, grade, ER
or PgR status.
Survival analysis
Follow-up data on vital status and date of last follow up were
available for 221 cases. Median 5-year survival time was 45
months (range 2–59 months) for the cases from Connecticut
and 54 months (range 3–60 months) for the cases from Cali-
fornia, and 52 months overall. Six of the 60 (10.0%) cases
from Connecticut and 24 of the 161 cases from California
(14.9%) died during the follow-up period.
Unknown 72 28.3
Progesterone receptor status
Positive 88 34.6
Negative 85 33.5
Borderline 3 1.2
Unknown 78 30.7
Method of breast cancer detection
Self examination 205 80.7
Physician examination 19 7.5
Mammography 17 6.7
Other 12 4.7
Missing 1 0.4
Table 1 (Continued)
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Table 2
Association of stage of breast cancer diagnosis and reproductive and family history variables
Reproductive and family history 
characteristics
Localized (n = 131) Nonlocalized (n = 116) ORa 95% CI P
Age at menarche (years)b
<12 26 (19.8) 29 (25.4) 1.0 (ref)
≥  12 105 (80.2) 85 (74.6) 0.8 0.4–1.4 0.35
Age at first full-term pregnancy (years)
No full-term pregnancies 48 (36.6) 29 (25.0) 1.0 (ref)
<20 12 (9.2) 19 (16.4) 3.0 1.2–7.4 0.02
20–24 31 (23.7) 35 (30.2) 2.1 1.0–4.3 0.04
25–29 25 (19.1) 24 (20.7) 1.7 0.8–3.6 0.15
30–34 15 (11.4) 9 (7.8) 1.1 0.4–2.9 0.86
Trend <0.01
Total live births
0 48 (36.6) 29 (25.0) 1.0 (ref)
1–2 71 (54.2) 67 (57.8) 1.7 0.9–3.1 0.07
3 or more 12 (9.2) 20 (17.2) 3.1 1.3–7.7 0.01
Trend 0.01
Total miscarriages (gravid women)
0 69 (74.2) 67 (72.0) 1.0 (ref)
1 or more 24 (25.8) 26 (28.0) 1.2 0.6–2.3 0.59
Total induced abortions (gravid women)
0 65 (69.9) 59 (63.4) 1.0 (ref)
1 or more 28 (30.1) 34 (36.6) 1.2 0.7–2.3 0.51
Breastfeeding (parous women)
Never 25 (30.1) 26 (29.9) 1.0 (ref)
Ever 58 (69.9) 61 (70.1) 1.1 0.5–2.2 0.80
Months between last full-term pregnancy and diagnosis
No full-term pregnancy 48 (36.6) 29 (25.0) 1.0 (ref)
0–23 23 (17.6) 26 (22.4) 1.9 0.9–3.9 0.09
24 or more 60 (45.8) 61 (52.6) 1.9 1.0–3.5 0.05
Trend 0.06
Oral contraceptive use
Never 19 (14.5) 21 (18.1) 1.0 (ref)
Ever 112 (85.5) 95 (81.9) 0.8 0.4–1.5 0.43
Total months of oral contraceptive usecAvailable online http://breast-cancer-research.com/content/7/4/R541
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Reproductive variables examined in relation to survival were
stratified by stage and included number of full-term
pregnancies (0–1, ≥  2), age at first full-term pregnancy (<25
years, 25–34 years, no full-term pregnancies), time since last
pregnancy (gravid women: 0–23 months, ≥  24 months), and
lactation history (parous women: never, ever). When stratified
by stage, women with either localized or nonlocalized disease
who had two or more full-term pregnancies did not have signif-
icantly decreased survival as compared with women with no or
one full-term pregnancies (P = 0.19 and P = 0.15, respec-
tively; Fig. 1). However, in an unstratified analysis women with
two or more full-term pregnancies had significantly decreased
survival as compared with women with no or one full-term
pregnancies (P < 0.05). Age at first full-term pregnancy and
lactation history were not found to be significantly associated
with overall survival (P = 0.08 and P = 0.45, respectively).
However, gravid women with nonlocalized tumors who had
their last pregnancy within 2 years of diagnosis had borderline
decreased survival as compared with gravid women with non-
localized tumors who had their last pregnancy more than 2
years before diagnosis (P = 0.06), but this association was not
significant among women with localized tumors (P = 0.24; Fig.
2).
Cox proportional hazards regression was used to test the
association of reproductive variables (total full-term pregnan-
cies, age at first full-term pregnancy, and time since last preg-
nancy) with survival, adjusting for stage. In these separate
analyses, increased parity ≥  2 full-term pregnancies as com-
pared with 0–1 full-term pregnancies) was a significant predic-
tor of decreased survival (hazard ratio [HR] = 2.1, 95% CI =
1.0–4.5). Age at first full-term pregnancy and time since last
pregnancy were not found to be significantly associated with
risk for decreased survival (HR = 0.8, 95% CI = 0.3–1.9, and
HR = 0.5, 95% CI = 0.2–1.1, respectively).
None 19 (14.6) 21 (18.9) 1.0 (ref)
1–35 35 (26.9) 29 (26.1) 0.6 0.3–1.3 0.22
36–83 33 (25.4) 29 (26.1) 0.7 0.3–1.4 0.30
84 or more 43 (33.1) 32 (28.8) 0.6 0.3–1.2 0.17
Trend 0.46
Family history of breast or ovarian cancerd
No family history 109 (83.8) 95 (82.6) 1.0 (ref)
Mother or sister 21 (16.2) 20 (17.4) 1.2 0.6–2.3 0.67
aAnalyses adjusted for age at diagnosis and education (higher of self or spouse). bTwo records missing age at menarche. cSix records missing total 
months of oral contraceptive use. dTwo records were excluded because proband reported being adopted. CI, confidence interval; OR, odds ratio.
Table 2 (Continued)
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Figure 1
Survival by number of full-term pregnancies and stage Survival by number of full-term pregnancies and stage. (a) Localized 
tumors, 0–1 full-term pregnancies; (b) localized tumors, ≥  2 full-term 
pregnancies; (c) nonlocalized tumors, 0–1 full-term pregnancies; and 
(d) non-localized tumors, ≥ 2 full-term pregnancies (P = 0.19 for local-
ized tumors; P = 0.15 for nonlocalized tumors).
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Figure 2
Survival by time since last pregnancy and stage Survival by time since last pregnancy and stage. (a) Localized tumors, 
time since last pregnancy <24 months; (b) localized tumors, time since 
last pregnancy ≥  24 months; (c) nonlocalized tumors, time since last 
pregnancy <24 months; and (d) nonlocalized tumors, time since last 
pregnancy ≥  24 months (P = 0.24 for localized tumors; P = 0.06 for 
nonlocalized tumors).
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Table 3
Association of breast cancer grade by reproductive and family history variables
Reproductive and hormonal Grade 1–2 Grade 3–4 OR (for grade 95% CI P
Age at menarche (years)
<12 15 (18.8) 33 (25.4) 1.0 (ref)
≥  12 65 (81.2) 97 (74.6) 0.7 0.4–1.5 0.38
Age at first full-term pregnancy (years)
No full-term pregnancies 27 (33.3) 35 (26.5) 1.0 (ref)
<20 5 (6.2) 23 (17.4) 3.2 1.0–9.9 0.05
20–24 25 (30.9) 34 (25.8) 1.0 0.4–2.1 0.95
25–29 17 (21.0) 26 (19.7) 1.4 0.6–3.1 0.43
30–34 7 (8.6) 14 (10.6) 2.5 0.8–7.5 0.10
Trend 0.27
Total live births
0 27 (33.3) 35 (26.5) 1.0 (ref)
1–2 45 (55.6) 78 (58.3) 1.5 0.8–2.8 0.25
3 or more 9 (11.1) 19 (15.2) 1.7 0.6–4.6 0.30
Trend 0.22
Total miscarriages (gravid women)
0 50 (82.0) 73 (70.2) 1.0 (ref)
1 or more 11 (18.0) 31 (29.8) 2.0 0.9–4.5 0.08
Total induced abortions (gravid women)
0 40 (65.6) 68 (65.4) 1.0 (ref)
1 or more 21 (34.4) 36 (34.6) 1.0 0.5–1.9 0.92
Breastfeeding (parous women)
Never 15 (27.8) 34 (35.0) 1.0 (ref)
Ever 39 (72.2) 63 (65.0) 0.8 0.4–1.6 0.51
Months between last full-term pregnancy and diagnosis
No full-term pregnancy 27 (33.3) 35 (26.5) 1.0 (ref)
0–23 19 (23.4) 27 (20.4) 1.2 0.5–2.6 0.71
≥  24 35 (43.2) 70 (53.0) 1.7 0.9–3.5 0.12
Trend 0.12
Oral contraceptive use
Never 10 (12.4) 21 (15.9) 1.0 (ref)
Ever 71 (87.6) 111 (84.1) 0.7 0.3–1.6 0.42
Total months of oral contraceptive usebAvailable online http://breast-cancer-research.com/content/7/4/R541
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Discussion
Steroid hormones play an important role in the etiology of
breast cancer. Evidence has consistently linked endogenous
hormone exposure to breast cancer risk [15]. Estrogen has
been implicated to induce tumor promotion and/or progres-
sion by enhancing cell proliferation [16]. In the present study
it was hypothesized that events associated with increases in
estrogen levels in young women may influence the progres-
sion of breast tumors, resulting in a more rapidly developing
disease that presents at a later stage and ultimately has a
poorer prognosis. Breast cancer patients younger than 35
years were selected for the study because tumors in this
group tend to have the most aggressive profiles.
Factors associated with tumor characteristics
Parity
Assessment of reproductive histories of early-onset breast
cancer patients indicated that increased parity was associated
with diagnosis of nonlocalized disease. However, this associ-
ation did not extend to pregnancies ending in either spontane-
ous or induced abortion. This finding is consistent with a
recent study of breast cancer patients aged under 45 years
[17] that reported an association between increased parity
and overall mortality.
Recent pregnancy
Having a full-term pregnancy within the 2 years preceding
diagnosis was not found to be associated with later stage dis-
ease, higher grade, or ER or PgR status. These findings differ
from a recent study of breast cancer patients aged under 45
years [17], which found a recent full-term pregnancy (<2 years
before diagnosis) to be associated with disease that had
spread to the regional lymph nodes. It should be noted that the
present study included a younger population, which may rep-
resent a group more likely to have a delay in diagnosis as com-
pared with older premenopausal women.
Age at first full-term pregnancy
Another finding of the present study was that early age at first
full-term pregnancy was also associated with later stage dis-
ease compared with nulliparity. As the age at first full-term
pregnancy increased, the risk for having a diagnosis of nonlo-
calized disease decreased, although risk estimates for any age
at first full-term pregnancy were elevated as compared with
nulliparity. However, when this analysis was restricted to
include only parous women, no significant association
between age at first full-term pregnancy and stage was
apparent.
There is some previous evidence [18,19] that an early age at
first full-term pregnancy may be associated with poorer prog-
nosis. It should also be noted that an early age at first full-term
pregnancy has been demonstrated to be protective in terms of
lifetime risk for breast cancer [20], and this protective effect
may be explained by the process of differentiation of breast tis-
sue induced by a full-term pregnancy, resulting in lower sus-
ceptibility to carcinogenic influences. However, the present
study addresses the issue of tumor progression rather than the
risk for developing breast cancer, because only breast cancer
cases were included in these analyses. Therefore, events that
are believed to be protective in terms of breast cancer risk,
such as early age at first full-term pregnancy and increased
parity, may have an adverse effect on breast cancer progres-
sion for women who are diagnosed with the disease. Perhaps
the timing of reproductive events in relation to the initiation and
promotion of breast cancers is critical in determining whether
the effect may be harmful for women who develop breast can-
cer during their principal reproductive years. Several findings
of the present study support such a theory.
Lactation
Lactation is believed to be associated with decreased circulat-
ing levels of estrogen and progesterone, and was hypothe-
sized to be associated with earlier stage tumors, with less
aggressive profiles. Lactation among parous women was not
found to be associated with tumor stage. However, parous
women who reported that they had ever breastfed a child were
more likely to have ER-positive and PgR-positive tumors than
were parous women who had never breastfed a child. Lacta-
tion, therefore, was associated with tumor markers indicative
None 10 (13.2) 21 (16.0) 1.0 (ref)
1–35 24 (31.6) 32 (24.4) 0.8 0.4–2.0 0.68
36–83 17 (22.4) 38 (29.0) 1.5 0.6–3.7 0.35
84 or more 25 (32.9) 40 (30.5) 1.2 0.5–2.8 0.64
Trend 0.78
Family history of breast or ovarian cancerc
No family history 65 (80.2) 113 (86.9) 1.0 (ref)
Mother or sister 16 (19.8) 17 (13.1) 0.7 0.3–1.4 0.29
aAnalyses adjusted for age at diagnosis and education (higher of self or spouse). bFive records missing total months of oral contraceptive use. cTwo 
records were excluded because proband reported being adopted. CI, confidence interval; OR, odds ratio.
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Table 4
Association of estrogen receptor status and reproductive and family history variables
Reproductive and family 
history characteristics
ER-positive or borderline 
tumors (n = 95)
ER-negative tumors (n = 87) ORa 95% CI P
Age at menarche (years)b
<12 16 (17.0) 19 (22.4) 1.0 (ref)
≥  12 78 (83.0) 66 (77.6) 0.7 0.3–1.5 0.42
Age at first full-term pregnancy (years)
No full-term pregnancies 27 (28.4) 27 (31.0) 1.0 (ref)
<20 10 (10.5) 16 (18.4) 1.5 0.6–4.0 0.43
20–24 26 (27.4) 19 (21.8) 0.7 0.3–1.6 0.39
25–29 23 (24.2) 16 (18.4) 0.7 0.3–1.7 0.45
30–34 9 (9.5) 9 (10.3) 1.2 0.4–3.6 0.80
Trend 1.0
Total live births
0 27 (28.4) 27 (31.0) 1.0 (ref)
1–2 57 (60.0) 49 (56.3) 0.9 0.4–1.7 0.68
3 or more 11 (11.6) 11 (12.6) 1.0 0.3–2.8 0.97
Trend 0.86
Total miscarriages (gravid women)
0 61 (80.3) 42 (65.6) 1.0 (ref)
1 or more 15 (19.7) 22 (34.4) 2.1 1.0–4.6 0.05
Total induced abortions (gravid women)
0 48 (63.2) 44 (68.8) 1.0 (ref)
1 or more 28 (26.8) 20 (31.2) 0.7 0.4–1.5 0.42
Breastfeeding (parous women)
Never 12 (17.6) 29 (48.3) 1.0 (ref)
Ever 56 (82.4) 31 (51.7) 0.2 0.1–0.5 <0.001
Months between last full-term pregnancy and diagnosis
No full-term pregnancy 27 (28.4) 27 (31.0) 1.0 (ref)
0–23 19 (20.0) 16 (18.4) 0.9 0.4–2.0 0.71
≥  24 49 (51.6) 44 (50.6) 0.9 0.4–1.8 0.77
Trend 0.78
Oral contraceptive use
Never 19 (20.0) 12 (13.8) 1.0 (ref)
Ever 76 (80.0) 75 (86.2) 1.6 0.7–3.4 0.28
Total months of oral contraceptive usecAvailable online http://breast-cancer-research.com/content/7/4/R541
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of better prognosis. Another case–control study of women
aged 20–74 years [21] found that women who had ever
breastfed were at decreased risk for developing ER-positive/
PgR-negative (OR = 0.5, 95% CI = 0.3–0.8) and ER-nega-
tive/PgR-positive tumors (OR = 0.4, 05% CI = 0.2–0.8). In a
case-only analysis, lactation was not associated with ER-pos-
itive/PgR-positive or ER-negative/PgR-negative status.
Perhaps the difference in results between the present study
and the previous one [21] is in part attributable to the different
subpopulations of breast cancer patients. Both ER and PgR
status were demonstrated to vary with age, with older women
more likely to be diagnosed with tumors positive for these
markers [21]. It is possible that, again, the timing of events may
be important in determining the effect of lactation on hormone
receptor status of breast cancers. In other words, the stage of
progression of the breast tumor at the time of lactation may
influence whether there is an effect on expression of hormone
receptors, and this may differ in general by age of the patient.
Exogenous hormones
Exogenous hormone exposure, in the form of oral contracep-
tives, was also examined in relation to tumor characteristics.
This source of exogenous hormones was not associated with
tumor stage, grade, or ER or PgR status. Oral contraceptive
use was further examined by months of use, but no significant
associations between months of use and any of the tumor
characteristics emerged. Therefore, the present study does
not support an association between exogenous hormone use
and tumor presentation among early-onset breast cancer
patients.
Survival analysis
Survival analyses stratified by stage suggested that a recent
pregnancy (within 2 years of diagnosis) was associated with
decreased survival as compared with women who had not had
a recent pregnancy among women with nonlocalized tumors.
Thirty-eight per cent of the women with nonlocalized tumors
who had a recent pregnancy died within 5 years of diagnosis
as compared with 15% of the women who had not had a
recent pregnancy. This finding corresponds with previous
research reporting that a recent pregnancy has an adverse
effect on survival following breast cancer diagnosis
[9,10,17,22,23] and supports the idea that a recent preg-
nancy may be responsible for more rapid progression of
disease, resulting in poorer prognosis. The association was
not observed among women with localized tumors, perhaps
because the survival rate in these women is generally high.
Strengths and limitations
The hypotheses and findings presented here have biologic
plausibility because of the established relationship between
estrogen levels and both breast tissue proliferation and breast
cancer risk. Estrogen and other hormone exposures are known
to be affected substantially by pregnancy and other reproduc-
tive events. Therefore, it is biologically plausible that reproduc-
tive events may influence the progression of breast cancer
among women in their childbearing years via a hormonal
pathway.
Including only living cases at the time of the study might have
introduced a survival bias among participants. This might have
reduced the proportion of women in the study with advanced
stage disease. Participants were interviewed within 2 years
after diagnosis and, given that breast cancer is generally not a
rapidly fatal disease, this may not have introduced much bias.
In fact, fewer than 6% of potential participants died before
study contact overall.
Another limitation is that there was not much information avail-
able regarding screening practices. Although we do not
expect women in this age group to be receiving screening
mammography, it was not possible to adjust for the effect of
screening behavior (breast self examinations or clinical breast
examinations) in the analyses. Therefore, if some of the inde-
pendent variables such as parity and age at first full-term preg-
nancy are associated with screening practices, then the
effects of these independent variables may have been miscon-
None 19 (20.2) 12 (14.6) 1.0 (ref)
1–35 24 (25.5) 23 (28.0) 1.1 0.5–2.6 0.81
36–83 16 (17.0) 20 (24.4) 1.5 0.6–3.7 0.42
84 or more 35 (37.2) 27 (32.9) 0.9 0.4–2.1 0.85
Trend 0.78
Family history of breast or ovarian cancerd
No family history 75 (79.8) 71 (82.6) 1.0 (ref)
Mother or sister 19 (20.2) 15 (17.4) 0.9 0.4–1.9 0.72
aAnalyses adjusted for age at diagnosis and education (higher of self or spouse).
bThree records missing age at menarche. cSix records missing total months of oral contraceptive use. dTwo records were excluded because 
proband reported being adopted. CI, confidence interval; ER, estrogen receptor; OR, odds ratio.
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Table 5
Association of progesterone receptor status and reproductive and family history variables
Reproductive and family history 
characteristics
PgR-positive or borderline tumors 
(n = 91)
PgR-negative tumors (n = 85) ORa 95% CI P
Age at menarche (years)b
<12 14 (15.6) 21 (25.3) 1.0 (ref)
≥  12 76 (84.4) 62 (74.7) 0.6 0.3–1.2 0.14
Age at first full-term pregnancy
No full-term pregnancies 27 (29.7) 25 (29.4) 1.0 (ref)
<20 10 (11.0) 15 (17.6) 1.6 0.6–4.4 0.37
20–24 25 (27.5) 20 (23.5) 0.8 0.4–2.0 0.71
25–29 19 (20.9) 18 (21.2) 1.1 0.5–2.6 0.82
30–34 10 (11.0) 7 (8.2) 0.9 0.3–2.9 0.88
Trend 0.65
Total live births
0 27 (29.7) 25 (29.4) 1.0 (ref)
1–2 53 (58.2) 50 (58.8) 1.1 0.5–2.1 0.87
3 or more 11 (12.1) 10 (11.8) 1.0 0.3–2.9 1.00
Trend 0.95
Total miscarriages (gravid women)
0 54 (76.1) 45 (69.2) 1.0 (ref)
1 or more 17 (23.9) 20 (30.8) 1.4 0.7–3.0 0.38
Total induced abortions (gravid women)
0 46 (64.8) 44 (67.7) 1.0 (ref)
1 or more 25 (35.2) 21 (32.3) 0.8 0.4–1.7 0.65
Breastfeeding (parous women)
Never 14 (21.9) 25 (41.7) 1.0 (ref)
Ever 50 (78.1) 35 (58.3) 0.4 0.2–0.8 0.02
Months between last full-term pregnancy and diagnosis
No full-term pregnancy 27 (29.7) 25 (29.4) 1.0 (ref)
0–23 17 (18.7) 16 (18.8) 1.0 0.4–2.5 0.95
≥  24 47 (51.6) 44 (51.8) 1.1 0.5–2.2 0.87
Trend 0.87
Oral contraceptive use
Never 19 (20.9) 10 (11.8) 1.0 (ref)
Ever 72 (79.1) 75 (88.2) 2.0 0.8–4.6 0.11
Total months of oral contraceptive usecAvailable online http://breast-cancer-research.com/content/7/4/R541
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strued. However, it is likely that reproductive events such as
pregnancy and childbirth would be associated with more fre-
quent screening procedures because these events place
women in the health care system. If so, then the independent
effects of these variables on tumor characteristics may have
been underestimated.
It is possible that socioeconomic status (SES) confounded the
association between reproductive variables and tumor charac-
teristics. Study participants were not well characterized with
respect to SES. Education as a surrogate measure of SES
was included as a covariate in the analysis, although it was not
found to be significantly associated with any of the tumor char-
acteristics under study (stage, grade, or ER or PgR status).
Future studies should take care in characterizing participants
with respect to SES.
Adjuvant therapy information was not available for all partici-
pants and was not included in the survival analyses. It should
also be noted that a fairly small sample size limited the extent
of multivariate analyses that could be performed. Furthermore,
follow-up information was not available for the patients diag-
nosed in Massachusetts, which further limited the sample size
available for survival analyses. However, because breast can-
cer diagnosis at age under 35 years is a rare event, large sam-
ple sizes for population-based studies of this subgroup are
often not available, and this study made use of a resource of
such patients.
Conclusion
Reproductive events such as pregnancy play an important role
in the etiology of breast cancer. Whether the effect of preg-
nancy on breast cancer initiation or progression is protective
or harmful may depend on the timing of the event in relation to
the carcinogenesis process. Women who have had full-term
pregnancies, particularly beginning at an early age, have con-
sistently been observed to be at decreased lifetime risk for
developing breast cancer as compared with nulliparous
women or those who have a first full-term pregnancy at an
older age. This may be due in part to the differentiation of
breast tissue that occurs during a full-term pregnancy.
The findings of the present study suggest that for women diag-
nosed with breast cancer before age 35 years, increased par-
ity and an early age at first full-term pregnancy are associated
with more advanced stage at presentation. Because all of the
women in this study were breast cancer patients, it is possible
that the pregnancies had an adverse effect on progression of
a breast cancer that was already developing. However, this
study suggests that the pregnancy need not be particularly
recent to have the adverse effect. Therefore, if a woman has a
full-term pregnancy and has not already had a prior initiation
event, then the pregnancy would be expected to leave the
breast tissue more differentiated and less susceptible to car-
cinogenic influences in the long term. However, the findings of
the present study suggest that a full-term pregnancy may have
an adverse effect on a breast cancer that is developing. Stud-
ies documenting a transient increase in breast cancer risk fol-
lowing pregnancy also support this theory [6-8].
An understanding of the role of reproductive and hormonal
exposures in the etiology and progression of breast cancer in
young women highlights some of the age-related issues in
breast cancer research by emphasizing that well established
risk factors in older women may not have similar effects in the
disease process in younger women, whose diagnoses occur
nearer in time to reproductive events such as pregnancy.
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